Furthermore, in a murine model of JAK2V617F-driven cancer generated by injecting mice with JAK2V617F-expressing hematopoietic cells, treatment with Ruxolitinib decreased severity of splenomegaly and increased survival rates with suppression of cytokine signaling as shown by a corresponding decrease in proinflammatory cytokines including IL-6 and TNF- α [131]. The gene discussed is IL6; the disease is cancer.